Targeting Alzheimer's disease pathology: influence of nano-based drug delivery systems loaded with a combination of herbal and synthetic drugs.

IF 5.4
Mumtaz, Devika Unnithan, Aysha Bano, Ajay Pratap Singh Chauhan, Javed Ali, Mohammad Ahmed Khan
{"title":"Targeting Alzheimer's disease pathology: influence of nano-based drug delivery systems loaded with a combination of herbal and synthetic drugs.","authors":"Mumtaz, Devika Unnithan, Aysha Bano, Ajay Pratap Singh Chauhan, Javed Ali, Mohammad Ahmed Khan","doi":"10.1080/17425247.2025.2513440","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Alzheimer's Disease (AD) is a progressive neurological disorder marked by cognitive decline and memory loss. Current treatments, including acetylcholinesterase inhibitors (AChEIs) and NMDA receptor antagonists, provide only symptomatic relief due to poor Blood Brain Barrier (BBB) permeability and side effects. The integration of synthetic and natural drug combinations with nanotechnology offers a promising strategy to enhance drug delivery, efficacy, and overall therapeutic outcomes.</p><p><strong>Areas covered: </strong>This review explores the integration of herbal and synthetic drugs in nano-based delivery systems for AD treatment. It examines co-loading efficiency, release kinetics, and synergistic therapeutic benefits of dual-drug formulations. Additionally, it discusses target-specific ligand functionalization for improved BBB penetration and neuronal targeting, alongside a comparative analysis of dual- vs. single-drug formulations and their impact on disease progression and efficacy.</p><p><strong>Expert opinion: </strong>Current treatments mainly offer early symptomatic relief but fail to target multiple neurobiological mechanisms of AD. Combining established therapies with herbal drugs can enhance efficacy and reduce side effects. Co-loading synthetic drugs and phytoconstituents in one nanoformulation can improve targeted delivery, sustained release, and minimize systemic effects for better outcomes.</p>","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1-16"},"PeriodicalIF":5.4000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert opinion on drug delivery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17425247.2025.2513440","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Alzheimer's Disease (AD) is a progressive neurological disorder marked by cognitive decline and memory loss. Current treatments, including acetylcholinesterase inhibitors (AChEIs) and NMDA receptor antagonists, provide only symptomatic relief due to poor Blood Brain Barrier (BBB) permeability and side effects. The integration of synthetic and natural drug combinations with nanotechnology offers a promising strategy to enhance drug delivery, efficacy, and overall therapeutic outcomes.

Areas covered: This review explores the integration of herbal and synthetic drugs in nano-based delivery systems for AD treatment. It examines co-loading efficiency, release kinetics, and synergistic therapeutic benefits of dual-drug formulations. Additionally, it discusses target-specific ligand functionalization for improved BBB penetration and neuronal targeting, alongside a comparative analysis of dual- vs. single-drug formulations and their impact on disease progression and efficacy.

Expert opinion: Current treatments mainly offer early symptomatic relief but fail to target multiple neurobiological mechanisms of AD. Combining established therapies with herbal drugs can enhance efficacy and reduce side effects. Co-loading synthetic drugs and phytoconstituents in one nanoformulation can improve targeted delivery, sustained release, and minimize systemic effects for better outcomes.

靶向阿尔茨海默病病理学:草药和合成药物组合负载的纳米药物传递系统的影响。
简介:阿尔茨海默病(AD)是一种以认知能力下降和记忆丧失为特征的进行性神经系统疾病。目前的治疗方法,包括乙酰胆碱酯酶抑制剂(AChEIs)和NMDA受体拮抗剂,由于血脑屏障(BBB)渗透性差和副作用,只能提供症状缓解。将合成药物和天然药物结合纳米技术提供了一种很有前途的策略,可以增强药物传递、疗效和整体治疗结果。研究领域:本综述探讨了草药和合成药物在纳米递送系统中治疗阿尔茨海默病的整合。它检查了双药制剂的共载效率、释放动力学和协同治疗效益。此外,它还讨论了靶向特异性配体功能化以改善血脑屏障渗透和神经元靶向性,同时比较分析了双药和单药制剂及其对疾病进展和疗效的影响。观点:目前的治疗方案主要是在早期阶段提供症状缓解,而未能针对导致AD进展的多种神经生物学机制。鉴于此,将已有的治疗方法与草药结合起来,我们可以利用它们的联合作用来提高治疗效果并减轻副作用。此外,合成药物和植物成分在单一纳米制剂中的共同负载可以改善特定药物的递送,提供持续释放,降低全身副作用,从而获得更好的治疗结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信